DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will present early results from a Phase 1 clinical trial of its WEE1 inhibitor APR-1051 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago.
The presentation will feature findings from the first-in-human ACESOT-1051 study evaluating APR-1051 in patients with advanced solid tumors.
The abstract has been accepted for a poster session focused on molecularly targeted agents and tumor biology.
The presentation is scheduled for May 30, 2026, from 1:30 p.m. to 4:30 p.m. CDT, with Shiraj Sen, MD, PhD, of NEXT Oncology in Dallas serving as the presenting author.
Details of the clinical trial are available at ClinicalTrials.gov under identifier NCT06260514.
APR-1051 is an oral small-molecule inhibitor targeting WEE1 kinase, a regulator of cell division that is being studied for its potential to treat cancers with specific genetic mutations.
Aprea is also developing ATRN-119, an ATR inhibitor, as part of its pipeline targeting biomarker-defined cancers, including ovarian, endometrial, colorectal, and head and neck cancers.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.